These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21371587)

  • 1. Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology.
    Böttcher J; Jestel A; Kiefersauer R; Krapp S; Nagel S; Steinbacher S; Steuber H
    Methods Enzymol; 2011; 493():61-89. PubMed ID: 21371587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Informatics and modeling challenges in fragment-based drug discovery.
    Hubbard RE; Chen I; Davis B
    Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences in fragment-based lead discovery.
    Hubbard RE; Murray JB
    Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electron density guided fragment-based drug design--a lead generation example.
    Abad MC; Gibbs AC; Zhang X
    Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry inspired fragment-based drug discovery.
    Lanter J; Zhang X; Sui Z
    Methods Enzymol; 2011; 493():421-45. PubMed ID: 21371600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput protein crystallography and drug discovery.
    Tickle I; Sharff A; Vinkovic M; Yon J; Jhoti H
    Chem Soc Rev; 2004 Oct; 33(8):558-65. PubMed ID: 15480479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
    Deng Z; Chuaqui C; Singh J
    J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel strategy for three-dimensional fragment-based lead discovery.
    Yuan H; Lu T; Ran T; Liu H; Lu S; Tai W; Leng Y; Zhang W; Wang J; Chen Y
    J Chem Inf Model; 2011 Apr; 51(4):959-74. PubMed ID: 21438547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based drug discovery and protein targets in the CNS.
    Hubbard RE
    Neuropharmacology; 2011 Jan; 60(1):7-23. PubMed ID: 20673774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational approach to de novo discovery of fragment binding for novel protein states.
    Konteatis ZD; Klon AE; Zou J; Meshkat S
    Methods Enzymol; 2011; 493():357-80. PubMed ID: 21371598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based lead discovery using X-ray crystallography.
    Hartshorn MJ; Murray CW; Cleasby A; Frederickson M; Tickle IJ; Jhoti H
    J Med Chem; 2005 Jan; 48(2):403-13. PubMed ID: 15658854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment shuffling: an automated workflow for three-dimensional fragment-based ligand design.
    Nisius B; Rester U
    J Chem Inf Model; 2009 May; 49(5):1211-22. PubMed ID: 19413347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lead optimization via high-throughput molecular docking.
    Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
    Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.